First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The investment will enable the company to enter European markets as well as enhance margins in current markets
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
To focus on providing safer burn treatments for women and armed forces
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
Subscribe To Our Newsletter & Stay Updated
